Skip to main content Accessibility help
×
Home
  • Print publication year: 2008
  • Online publication date: August 2009

3 - Normal blood glucose regulation and diabetes

Summary

Blood glucose levels in the individual without diabetes remain remarkably stable, approximately between 4 and 7 mmol/l, even if the individual fasts for several hours or consumes a large sugary meal. This level is maintained by a relationship between insulin, which lowers blood glucose, and the counter-regulatory hormones (primarily glucagon), which cause a rise in blood glucose (Table 3.1). The efficiency of this system is often not appreciated until the prescriber tries to support the patient with diabetes to mimic these same effects and achieve near normoglycaemia with the various manufactured insulins available!

Insulin is produced by the beta cells in the islets of Langerhans, embedded in the pancreas gland (which also produces pancreatic digestive juices, a function that is not affected in diabetes). After a carbohydrate load in the gut following eating, starch and sugars are broken down into glucose by digestive juices. Glucose is then absorbed from the gut into the blood circulation. Receptors in the beta cells monitor the prevailing blood glucose. In the individual without diabetes, the resulting rise in blood glucose after a meal stimulates the beta cells to produce a burst of insulin, which prevents blood glucose from rising much above 7 mmol/l. As the blood glucose falls to normal as feeding finishes, beta cell stimulation is reduced and insulin production also falls in response.

During periods of fasting, low blood glucose concentrations result in minimal stimulation of the beta cells, so production of insulin is low.

References
Amos, A. F., McCarty, D. J. and Zimmet, P. (1997) The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabetic Medicine 14(Suppl. 5): S1–S85.
Baxter, H., Bottomley, J., Burns, E.et al. (2000) CODE-2 UK. The annual direct costs of care for people with type 2 diabetes in Great Britain. Diabetic Medicine 17(Suppl. 1): 13.
,Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England Journal of Medicine 329: 977–86.
,DoH (2001) National Service Framework for Diabetes: Standards. London: The Stationery Office.
Donnan, P. T., MacDonald, T. M. and Morris, A. D. (2002) Adherence to prescribed oral hypoglycaemic medication in a population of patients with type 2 diabetes: a retrospective cohort study. Diabetes Medicine 19: 279–84.
,International Diabetes Federation (2005) The IDF Consensus Worldwide Definition of the Metabolic Syndrome. Brussels: International Diabetes Federation. Available at www.idf.org/webdata/docs/IDF/Metasyndrome/definition.pdf,2005 (January accessed 26 2007).
Stratton, I. M., Adler, A. I. and Andrew, H. (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. British Medical Journal 321: 405–12.
Turner, R., Holman, R., Stratton, I., for the ,UK Prospective Diabetes Study (UKPDS) Group (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. British Medical Journal 317: 703–13.
,UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837–53.
Watkins, P. (1998) ABC of Diabetes. London: BMJ Publishing.
,World Health Organization (1999) Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Part 1. Diagnosis and Classification of Diabetes Mellitus. Geneva: World Health Organization.
Wright, A., Burden, A. C., Paisley, R. B., Cull, C. A. and Holman, R. R. (2002) Sulfonyl inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK Prospective Diabetes Study (UKPDS 57). Diabetes Care 25: 330–6.